PMEL and neoplasm: Tumors display a wide variety of (abnormally expressed) tumor-associated antigens (TAA), and TAAs such as MART-1, MUC1, WT1, gp100 and the MAGE-A antigens, have been tested in various vaccines in clinical trials (79–82).